Methylphenidate Extended Release Chewable Tablet

• US 20170216270A1
• Filed: 04/19/2017
• Published: 08/03/2017
• Est. Priority Date: 08/15/2012
• Status: Active Grant

• Current Assignee: Tris Pharma Incorporated
• Original Assignee: Tris Pharma Incorporated
• Inventors: Perumal, Ashok, Kathala, Kalyan, Tu, Yu-Hsing
• Granted Patent: US 9,844,545 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/4458 only substituted in position 2, e.g. methylphenidate
• CPC Class Codes: A61K 47/585 Ion exchange resins, e.g. polystyrene sulfonic acid resin
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2072 characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/0004, A61K9/0056, A61K9/0065 take precedence
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/2081 with microcapsules or coated microparticles according to A61K9/50
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/28 Dragees; Coated pills or tablets , e.g. with film or compression coating A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209
• CPC Class Codes: A61K 9/284 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

Claims

1-3. -3. (canceled)

4. An extended release racemic methylphenidate chewable tablet, wherein the chewable tablet is a solid dispersion comprising:

(a) a sustained release, racemic methylphenidate component comprising a water-insoluble, water-permeable, pH-independent barrier coated, racemic methylphenidate-cation exchange resin complex which comprises;

(i) a racemic methylphenidate-cation exchange resin complex comprising racemic methylphenidate and a pharmaceutically acceptable cation ion exchange resin, wherein the racemic methylphenidate is bound to the pharmaceutically acceptable cation exchange resin;

(ii) a water-insoluble, water-permeable, pH-independent, barrier coating comprising cellulose acetate and a plasticizer;

wherein the barrier coating provides a sustained release profile to the racemic methylphenidate; and

wherein about 50% w/w to about 90% w/w of total racemic methylphenidate in the chewable tablet is provided by the sustained release component; and

(b) an immediate racemic methylphenidate component comprising an racemic methylphenidate-cation exchange resin complex which provides a release of the racemic methylphenidate in less than about 30 minutes as determined in an in vitro dissolution assay, wherein the methylphenidate-cation exchange resin complex comprises racemic methylphenidate bound to a pharmaceutically acceptable cation exchange resin;

wherein the chewable tablet is capable of being divided and providing tablet portions which retain a therapeutically effective extended release profile, and a pharmacokinetic profile in which the racemic methylphenidate has at least one of;

a geometric mean for area under the curve (AUC)_0-∞

of about 110 ng-hr/mL to about 140 ng-hr/mL or a geometric mean C_max of about 10 ng/mL to about 15 ng/mL, under fasted conditions in adults following a single oral administration of the chewable tablet which has a total amount of racemic methylphenidate which is the equivalent of 40 mg racemic methylphenidate HCl.

5. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the plasticizer is selected from propylene glycol, polyethylene glycol, dibutyl sebacate, propylene glycol, polyethylene glycol, polyvinyl alcohol, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, tributyl citrate, triacetin, 2-pyrrolidone, or mixtures thereof.

6. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the plasticizer comprises triethyl citrate.

7. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the plasticizer comprises polyethylene glycol.

8. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the plasticizer is present in an amount of about 2% w/w to about 20% w/w of the barrier coating.

9. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the plasticizer is present in an amount of about 2.5% w/w to about 10% w/w of the barrier coating.

10. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the barrier coating is applied as a solvent based suspension.

11. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the barrier coating is cured.

12. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the barrier coat has a tensile strength in the range of at least about 150% to about 400% as measured by a texture analyzer.

13. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the water-insoluble, water-permeable, pH-independent polymer is present in the barrier coat an amount of about 70% to about 90% w/w, based on the weight of the final barrier coating layer.

15. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the barrier coat is present in an amount of about 20% w/w to about 50% w/w % based on the weight of the racemic methylphenidate-cation exchange resin complex of (ii).

16. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the barrier coat is present in an amount of about 20% w/w to about 35% w/w % based on the weight of the racemic methylphenidate-cation exchange resin complex of (ii).

17. The extended release racemic methylphenidate chewable tablet according to claim 16, wherein the immediate release component comprises about 20% w/w to about 40% w/w of the total racemic methylphenidate in the chewable tablet.

18. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the barrier coated methylphenidate-cation exchange resin complex as defined in (ii) are particulates having a mean particle size in the range of about 100 microns to about 450 microns.

19. The extended release racemic methylphenidate chewable tablet according to claim 18, wherein the barrier coated methylphenidate-cation exchange resin complex as defined in (ii) are particulates having a mean particle size in the range of about 150 microns to about 300 microns.

20. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the sustained release methylphenidate component provides about 60% w/w to about 80% w/w of the methylphenidate in the chewable tablet, based on the total amount of methylphenidate in the chewable tablet.

21. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the tablet has a hardness in the range of about 8 kp to about 23 kp.

22. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the in vitro dissolution assay is performed placing the tablet in 900 mL 0.4 M potassium phosphate buffer with 37°

C.±

5°

C. with a USP paddle speed of 75 rpm.

23. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the tablet has a pharmacokinetic profile for racemic methylphenidate comprising a single mean plasma concentration peak which is about 4 hours to about 5.25 hours under fasted conditions.

24. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein pharmacokinetic profile further comprises the 90% confidence intervals of the geometric mean test/reference ratios of one or more of AUC0-3 or AUC0-4 of FIG. 1.

25. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the AUC0-3 is bioequivalent to about 18 ng-hr/mL.

26. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein the methylphenidate plasma concentration, as determined under fasted and fed conditions following a single oral administration of said chewable tablet at a dose equivalent to 40 mg racemic methylphenidate HCl in adults, is equivalent to the plasma concentration curve of FIG. 1 from about 0 to about 8 hours.

27. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein said tablet comprises the equivalent of 40 mg racemic methylphenidate HCl.

28. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein said tablet comprises the equivalent of 20 mg racemic methylphenidate HCl.

29. The extended release racemic methylphenidate chewable tablet according to claim 4, wherein said tablet is scored.

30. A method for treating a patient with a disorder treatable by methylphenidate, said method comprising dosing said patient with an effective amount of a methylphenidate extended release chewable tablet according to claim 4.

31. The method according to claim 30, wherein said patient has been diagnosed with attention deficit hyperactivity disorder, postural orthostatic tachycardia syndrome, or narcolepsy.

32. The method according to claim 31, wherein said patient has attention deficit hyperactivity disorder.

33. The method according to claim 30, wherein the patient swallows the tablet intact.